Skip to content
drillr.ai

ABOS

Acumen Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$2.21-1.78%

Price as of Jul 20, 2026

ABOS news

Acumen Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

    NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=p6SjXfkj3hQFJWnuAHkowhXH4A88MfqqjJ273TZOueGuCQABgd3EYiOmYT5X-_LW-7LnNr6h37RTN69E_5P-drlKa7er3ySXgZtEDE4sGm7HLeTulnC23aMXb50xeD7vQ6c1ICzzWmbkBNJYRI8kZFjsbXdtJpsvCS7bJYkjXU3y5HXKURU_PZeycPqhDTRWVXS9P0-rEW83OC4iFvUaL8m9JOugXwl_q-YYU4DMRJcZ4APof_3EHq8cJ74c0mcbOGzIGspKgzYEzjFxoTJCSw==) (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutic

    Globe Newswire ·

  2. JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

    JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo(®) Technology Platform - Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo(®) to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease - Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2

    Business Wire ·

  3. Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

    NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=wWeyqc9r5OEatBpFhZ1VtUZJyrRBpFS8XGzntVfkMvUgV0_7VYastPW6JW4CGAWZaDTkiyFtyVxfSEC9YuZqY550gD6epwL4TqZFV3nszng=) (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter fi

    Globe Newswire ·

  4. Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

    NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=QY6bOSvufPuHQcHM7jPVjF6XaA3MS7AyrLMbEB7MCJwfR618b2wwphun_Zilps7UR46RaysqVJKkc_Wp49mq9NJly8a4rDtEgLTyaiLqC5Q=) (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter

    Globe Newswire ·

  5. Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

    * Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen’s transferrin-receptor targeting Enhanced Brain Delivery (EBD™) program * Candidates exceeded key preclinical criteria, demonstrating elevated brain exposure in non-human primates up to 40-fold over native antibodies, low risk of anemia, and robust stability profiles to enable subcuta

    Globe Newswire ·

  6. Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

    NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=miSn7hFmX2ega561eKdQK2XZ2_4AXkf35nv8tNKbXvP2mLIiXDsKEJQv0Qb2meJcn2JTbMOLtBdch_7OLZMYGhdfrrFr3rlQHPp4kobmHYQ=) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2026

    Globe Newswire ·